What is the current Price Target for the Chemomab Therapeutics Ltd - ADR stock?

The average Chemomab Therapeutics Ltd - ADR target price is $27.03. This is 923.86% higher than the current stock price. The highest price target is 1,013.64%, the lowest is 856.44%. 4 Analysts have issued a price target Chemomab Therapeutics Ltd - ADR 2026 .

How high will the Chemomab Therapeutics Ltd - ADR stock rise?

No reliable answer can be given as to how high the Chemomab Therapeutics Ltd - ADR stock will rise. The performance of stocks, including the Chemomab Therapeutics Ltd - ADR stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Chemomab Therapeutics Ltd - ADR stock today?

The performance of Chemomab Therapeutics Ltd - ADR stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Chemomab Therapeutics Ltd - ADR stock fall?

The decline in Chemomab Therapeutics Ltd - ADR stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Chemomab Therapeutics Ltd - ADR Forecast, price target & analysts

$2.64

2.33% yesterday

Nasdaq, Nov 07, 10:00 pm CET

ISIN

US16385C1045

Symbol

CMMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Chemomab Therapeutics Ltd - ADR Target price 2025 - Analyst rating & recommendation

Chemomab Therapeutics Ltd - ADR Classifications & Recommendation:

Buy

88%

Hold

13%

Chemomab Therapeutics Ltd - ADR Price Target

Target Price	$27.03
Price	$2.64
Potential	923.86% register free of charge
Number of Estimates	4

	4 Analysts have issued a price target Chemomab Therapeutics Ltd - ADR 2026 . The average Chemomab Therapeutics Ltd - ADR target price is $27.03. This is 923.86% register free of charge higher than the current stock price. The highest price target is $29.40 1,013.64% register free of charge , the lowest is $25.25 856.44% register free of charge .
	A rating was issued by 8 analysts: 7 Analysts recommend Chemomab Therapeutics Ltd - ADR to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Chemomab Therapeutics Ltd - ADR stock has an average upside potential 2026 of 923.86% register free of charge . Most analysts recommend the Chemomab Therapeutics Ltd - ADR stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.16	-0.16
	60.98%	0.00%
P/E		negative

3 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast for earnings per share. The average Chemomab Therapeutics Ltd - ADR EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.16	60.98%
2025	$-0.16 0.00% Unlock
2026	$-0.16 0.00% Unlock
2027	$-0.20 25.00% Unlock
2028	$-0.16 20.00% Unlock
2029	$-0.16 0.00% Unlock
2030	$-0.20 25.00% Unlock
2031	$1.88 1,040.00% Unlock
2032	$2.98 58.51% Unlock

Current	-25.80	6.52%
2025	-15.81 38.72% Unlock
2026	-15.81 0.00% Unlock
2027	-12.65 19.99% Unlock
2028	-15.81 24.98% Unlock
2029	-15.81 0.00% Unlock
2030	-12.65 19.99% Unlock

Chemomab Therapeutics Ltd - ADR...

Current Chemomab Therapeutics Ltd - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Oppenheimer	Locked ➜ Locked	Locked	Aug 27 2025
Oppenheimer	Locked ➜ Locked	Locked	May 16 2025
Maxim Group	Locked ➜ Locked	Locked	Feb 20 2025
Oppenheimer	Locked ➜ Locked	Locked	Nov 15 2024

Analyst Rating	Date
Locked Oppenheimer: Locked ➜ Locked	Aug 27 2025
Locked Oppenheimer: Locked ➜ Locked	May 16 2025
Locked Maxim Group: Locked ➜ Locked	Feb 20 2025
Locked Oppenheimer: Locked ➜ Locked	Nov 15 2024

Discover more stocks with a high price target

Novo Nordisk 60.25%

TUI 59.01%

Adidas 53.11%

Deutsche Telekom 45.39%

Meta Platforms (Facebook) 43.56%

Adyen 39.97%

BYD 38.89%

BioNTech SE - ADR 34.99%

Coinbase Global, Inc. 33.30%

Infineon 30.91%

Microsoft 29.34%

Netflix 28.46%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now